Clinical Trials · NCT00605267
Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 197
- Start date
- Oct 2007
- Locations
- 4 sites, Japan
- Primary endpoint
- Best Overall Response Rate (BORR) (Calliper)